Alefacept Biogen

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 631-634

  Bashir, S J ^a   Maibach, H I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; B 9273; CD2 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PLACEBO; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BOLUS INJECTION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FLU LIKE SYNDROME; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HEART TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INJURY; NAUSEA; NONHUMAN; PHARYNGITIS; PSORIASIS; RETREATMENT; REVIEW; RHINITIS; SINUSITIS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TOXICITY TESTING; TREATMENT OUTCOME; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD2; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034980467     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice
2. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival
3. LFA3TIP delays rejection of baboon heterotopic cardiac allografts and inhibits immune responses of human CD2 transgenic mice
4. Biogen: Will cell surface markers pave the way?
5. Biogen announces that Amevive shows excellent dose response with positive side-effect profile in phase II psoriasis study
6. Pharmacokinetics of LFA3TIP (Amevive) in chronic plaque psoriasis patients during repeated once-weekly intravenous administration
7. Investigators present positive results of phase II study of AMEVIVE (recombinantly engineered LFA-1/IgG1 human fusion protein) at a meeting in London - Biogen begins phase III trials with AMEVIVE(TM) for the treatment of patients with chronic plaque psoriasis
8. Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): Selective modulation of CD45RO+ lymphocytes
9. Biogen reports first quarter 2000 results
10. Biogen reports second quarter 2000 results - Record revenues and number of Avonex patients reported
11. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers
12. The response of chronic plaque psoriasis to Amiveve™ (LFA3TIP) and the selective suppression of peripheral memory/effector T cells (CD45RO+) versus nave T cells (CD45RA+) is linked to serum levels of LFA3TIP
13. Biogen reports third quarter 2000 results - Collaborations bolster the company's pipeline development efforts
14. Biogen says it expects number of drugs in clinical pipeline to double in 2001
15. Biogen Inc.
16. AMEVIVE phase II clinical trial on retreatment of patients with moderate to severe chronic plaque psoriasis presented at American Academy of Dermatology
17. Presentations at the American Academy of Dermatology
18. Biogen Inc